TELA Bio, Inc.

For the period ended Dec 31, 2024. Filed Mar 21, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 21, 2025

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)


· · Year ended December 31,
· 2024 · · 2023 · 2022
Cash flows from operating activities:
Net loss	$(37,841)	$(46,664)	$(44,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	632	428	383
Noncash interest expense	609	599	657
Noncash loss on extinguishment of debt	—	—	1,228
Amortization of intangible assets	380	380	804
Net changes in operating lease ROU assets and liabilities	(99)	(49)	(36)
Inventory excess and obsolescence charge	2,955	1,414	1,866
Stock‑based compensation expense	4,362	5,032	3,989
Deferred income tax benefit	(144)	—	—
Gain on disposal of fixed assets	—	(12)	—
Gain on sale of product line	(7,580)	—	—
Change in operating assets and liabilities:
Accounts receivable, net	(762)	(3,058)	(2,421)
Inventory	(2,972)	(2,718)	(6,073)
Prepaid expenses and other current assets	227	(81)	1,216
Accounts payable	482	11	(884)
Accrued expenses and other current and long-term liabilities	(1,809)	4,177	2,399
Foreign currency transaction (gain) loss	(35)	(316)	420
Net cash used in operating activities	(41,595)	(40,857)	(40,748)
Cash flows from investing activities:
Payment for intangible asset	—	—	(1,000)
Purchase of property and equipment	(989)	(611)	(872)
Proceeds from the sale of product line	5,440	—	—
Proceeds from the sale of property and equipment	—	12	—
Net cash provided by (used in) investing activities	4,451	(599)	(1,872)
Cash flows from financing activities:
Proceeds from sale of common stock and pre-funded warrants, net	42,919	46,341	34,400
Proceeds from issuance of long-term debt	—	—	40,000
Repayment of long-term debt	—	—	(30,000)
Payment of debt financing costs	—	—	(3,460)
Proceeds from exercise of stock options	226	127	19
Payment of withholding taxes related to stock-based compensation to employees	(369)	(289)	(157)
Proceeds from issuance of common stock under the employee stock purchase plan	281	88	50
Net cash provided by financing activities	43,057	46,267	40,852
Effect of exchange rate on cash and cash equivalents	28	164	(144)
Net increase (decrease) in cash and cash equivalents and restricted cash	5,941	4,975	(1,912)
Cash and cash equivalents and restricted cash, beginning of year	46,994	42,019	43,931
Cash and cash equivalents and restricted cash, end of year	$52,935	$46,994	$42,019
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$4,071	$4,624	$3,394
Supplemental disclosures of noncash investing and financing activities:
Property and equipment in accounts payable and accrued expenses and other current liabilities	$—	$119	$7
Operating lease ROU asset exchanged for operating lease liabilities	$—	$895	$1,376
Tenant improvement and deferred rent reclassified to operating lease liabilities	$—	$—	$380
Operating lease liabilities assumed for operating lease ROU assets	$—	$—	$1,756

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.